Fugen Laboratories Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 16-12-2024
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Satisfied Charges ₹ 8.88 Cr
as on 16-12-2024
- Revenue -92.87%
(FY 2021)
- Profit -5447.19%
(FY 2021)
- Ebitda -110.51%
(FY 2021)
- Net Worth -17.33%
(FY 2021)
- Total Assets 36.53%
(FY 2021)
About Fugen Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company has closed loans amounting to ₹8.88 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nagamani Kaperla, Varunkumarreddy Koduru, and Ramakanth Katta serve as directors at the Company.
- CIN/LLPIN
U24231TG2005PTC045207
- Company No.
045207
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 2005
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Nalgonda, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Fugen Laboratories Private Limited offer?
Fugen Laboratories Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API.
Who are the key members and board of directors at Fugen Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagamani Kaperla  | Additional Director | 11-Jan-2021 | Current |
| Varunkumarreddy Koduru | Additional Director | 11-Jan-2021 | Current |
| Ramakanth Katta | Additional Director | 11-Jan-2021 | Current |
Financial Performance of Fugen Laboratories.
Fugen Laboratories Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 92.87% decrease. The company also saw a substantial fall in profitability, with a 5447.19% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fugen Laboratories?
In 2021, Fugen Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Manvi Biopharma Private LimitedActive 6 years 2 monthsNagamani Kaperla, Varunkumarreddy Koduru and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Sep 2018 | ₹2.39 Cr | Satisfied |
Andhra Pradesh State Financial Corporation Creation Date: 09 May 2013 | ₹1.69 Cr | Satisfied |
Indian Bank Creation Date: 08 Aug 2011 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Fugen Laboratories?
Fugen Laboratories has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fugen Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fugen Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
